Practical guidance for CD management involving treatment of botulinum toxin: a consensus statement

Cervical dystonia is a neurological movement disorder causing abnormal posture of the head. It may be accompanied by involuntary movements which are sometimes tremulous. The condition has marked effects on patients’ self-image, and adversely affects quality of life, social relationships and employme...

Full description

Bibliographic Details
Main Authors:	Albanese, Alberto, Abbruzzese, Giovanni, Dressler, Dirk, Duzynski, Wojciech, Khatkova, Svetlana, Marti, Maria Jose, Mir, Pablo, Montecucco, Cesare, Moro, Elena, Pinter, Michaela, Relja, Maja, Roze, Emmanuel, Skogseid, Inger Marie, Timerbaeva, Sofiya, Tzoulis, Charalampos
Format:	Online
Language:	English
Published:	Springer Berlin Heidelberg 2015
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4608989/

id	pubmed-4608989
recordtype	oai_dc
spelling	pubmed-46089892015-10-21 Practical guidance for CD management involving treatment of botulinum toxin: a consensus statement Albanese, Alberto Abbruzzese, Giovanni Dressler, Dirk Duzynski, Wojciech Khatkova, Svetlana Marti, Maria Jose Mir, Pablo Montecucco, Cesare Moro, Elena Pinter, Michaela Relja, Maja Roze, Emmanuel Skogseid, Inger Marie Timerbaeva, Sofiya Tzoulis, Charalampos Review Cervical dystonia is a neurological movement disorder causing abnormal posture of the head. It may be accompanied by involuntary movements which are sometimes tremulous. The condition has marked effects on patients’ self-image, and adversely affects quality of life, social relationships and employment. Botulinum neurotoxin (BoNT) is the treatment of choice for CD and its efficacy and safety have been extensively studied in clinical trials. However, current guidelines do not provide enough practical information for physicians who wish to use this valuable treatment in a real-life setting. In addition, patients and physicians may have different perceptions of what successful treatment outcomes should be. Consequently, an international group of expert neurologists, experienced in BoNT treatment, met to review the literature and pool their extensive clinical experience to give practical guidance about treatment of CD with BoNT. Eight topic headings were considered: the place of BoNT within CD treatment options; patient perspectives and desires for treatment; assessment and goal setting; starting treatment with BoNT-A; follow-up sessions; management of side effects; management of non-response; switching between different BoNT products. One rapporteur took responsibility for summarising the current literature for each topic, while the consensus statements were developed by the entire expert group. These statements are presented here along with a discussion of the background information. Springer Berlin Heidelberg 2015-04-01 2015 /pmc/articles/PMC4608989/ /pubmed/25877834 http://dx.doi.org/10.1007/s00415-015-7703-x Text en © The Author(s) 2015 Open AccessThis article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.
repository_type	Open Access Journal
institution_category	Foreign Institution
institution	US National Center for Biotechnology Information
building	NCBI PubMed
collection	Online Access
language	English
format	Online
author	Albanese, Alberto Abbruzzese, Giovanni Dressler, Dirk Duzynski, Wojciech Khatkova, Svetlana Marti, Maria Jose Mir, Pablo Montecucco, Cesare Moro, Elena Pinter, Michaela Relja, Maja Roze, Emmanuel Skogseid, Inger Marie Timerbaeva, Sofiya Tzoulis, Charalampos
spellingShingle	Albanese, Alberto Abbruzzese, Giovanni Dressler, Dirk Duzynski, Wojciech Khatkova, Svetlana Marti, Maria Jose Mir, Pablo Montecucco, Cesare Moro, Elena Pinter, Michaela Relja, Maja Roze, Emmanuel Skogseid, Inger Marie Timerbaeva, Sofiya Tzoulis, Charalampos Practical guidance for CD management involving treatment of botulinum toxin: a consensus statement
author_facet	Albanese, Alberto Abbruzzese, Giovanni Dressler, Dirk Duzynski, Wojciech Khatkova, Svetlana Marti, Maria Jose Mir, Pablo Montecucco, Cesare Moro, Elena Pinter, Michaela Relja, Maja Roze, Emmanuel Skogseid, Inger Marie Timerbaeva, Sofiya Tzoulis, Charalampos
author_sort	Albanese, Alberto
title	Practical guidance for CD management involving treatment of botulinum toxin: a consensus statement
title_short	Practical guidance for CD management involving treatment of botulinum toxin: a consensus statement
title_full	Practical guidance for CD management involving treatment of botulinum toxin: a consensus statement
title_fullStr	Practical guidance for CD management involving treatment of botulinum toxin: a consensus statement
title_full_unstemmed	Practical guidance for CD management involving treatment of botulinum toxin: a consensus statement
title_sort	practical guidance for cd management involving treatment of botulinum toxin: a consensus statement
description	Cervical dystonia is a neurological movement disorder causing abnormal posture of the head. It may be accompanied by involuntary movements which are sometimes tremulous. The condition has marked effects on patients’ self-image, and adversely affects quality of life, social relationships and employment. Botulinum neurotoxin (BoNT) is the treatment of choice for CD and its efficacy and safety have been extensively studied in clinical trials. However, current guidelines do not provide enough practical information for physicians who wish to use this valuable treatment in a real-life setting. In addition, patients and physicians may have different perceptions of what successful treatment outcomes should be. Consequently, an international group of expert neurologists, experienced in BoNT treatment, met to review the literature and pool their extensive clinical experience to give practical guidance about treatment of CD with BoNT. Eight topic headings were considered: the place of BoNT within CD treatment options; patient perspectives and desires for treatment; assessment and goal setting; starting treatment with BoNT-A; follow-up sessions; management of side effects; management of non-response; switching between different BoNT products. One rapporteur took responsibility for summarising the current literature for each topic, while the consensus statements were developed by the entire expert group. These statements are presented here along with a discussion of the background information.
publisher	Springer Berlin Heidelberg
publishDate	2015
url	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4608989/
_version_	1613489349887787008

Practical guidance for CD management involving treatment of botulinum toxin: a consensus statement

Similar Items